title: [A case of HER2-positive advanced gastric cancer successfully treated with a combination of capecitabine, cisplatin, and trastuzumab as first-line chemotherapy].
abstract: We report a case of human epidermal growth factor receptor(HER)2-positive advanced gastric cancer successfully treated with a combination of capecitabine, cisplatin(CDDP), and trastuzumab as first-line chemotherapy. A 66-year-old woman diagnosed as having advanced gastric cancer underwent chemotherapy after abdominal computed tomography (CT)revealed multiple metastases to the liver, lung, lymph nodes, and peritoneum. Histopathological examination indicated a type 3, tub1, cT3(SS), N3, H1, P1, M1(LYM, PUL), cStage IV gastric tumor. Because overexpression of HER2 protein was observed in primary tumor immunostaining, combination therapy of capecitabine+CDDP+trastuzumab was administered as first-line chemotherapy. After 4 courses, CT scans revealed decreased primary tumor size, liver lesion, lymph nodes, and elimination of the lung lesion, thereby suggesting a partial response(PR). The grade 3 adverse events were neutropenia, anemia, and anorexia. After discontinuation of CDDP because of elevation of serum creatinine levels, combination therapy with capecitabine and trastuzumab was continued.
authors.affiliation: Dept. of Surgery, Osaka General Medical Center.
authors.forename: Koichi
authors.initials: K
authors.lastname: Deguchi
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Nishikawa
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Iwase
authors.forename: Junji
authors.initials: J
authors.lastname: Kawada
authors.forename: Toyokazu
authors.initials: T
authors.lastname: Aono
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Yoshida
authors.forename: Masaya
authors.initials: M
authors.lastname: Nomura
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Tamagawa
authors.forename: Chu
authors.initials: C
authors.lastname: Matsuda
authors.forename: Takashi
authors.initials: T
authors.lastname: Deguchi
authors.forename: Shigeyoshi
authors.initials: S
authors.lastname: Higashi
authors.forename: Yuichiro
authors.initials: Y
authors.lastname: Okumura
authors.forename: Yuki
authors.initials: Y
authors.lastname: Noguchi
authors.forename: Masatoshi
authors.initials: M
authors.lastname: Nomura
authors.forename: Mari
authors.initials: M
authors.lastname: Takagi
authors.forename: Akiko
authors.initials: A
authors.lastname: Fukui
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Tanaka
mesh_terms: D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000069287:Capecitabine; D002945:Cisplatin / Q000008:administration & dosage; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000031:analogs & derivatives; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy / Q000556:secondary; D008175:Lung Neoplasms / Q000188:drug therapy / Q000556:secondary; D008207:Lymphatic Metastasis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis*; D013274:Stomach Neoplasms / Q000737:chemistry / Q000188:drug therapy* / Q000473:pathology; D000068878:Trastuzumab
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000069287:Capecitabine; D002945:Cisplatin; D003841:Deoxycytidine; D005472:Fluorouracil; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab; C508053:ERBB2 protein, human